Publication: Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
cris.virtualsource.author-orcid | 657eb181-3137-4b10-9226-937f459da4de | |
cris.virtualsource.author-orcid | f618d47b-2349-48a6-a9b4-74989a01812f | |
datacite.rights | open.access | |
dc.contributor.author | Maul, Julia-Tatjana | |
dc.contributor.author | Djamei, Vahid | |
dc.contributor.author | Kolios, Antonios G A | |
dc.contributor.author | Meier, Barbara | |
dc.contributor.author | Czernielewski, Justine | |
dc.contributor.author | Jungo, Pascal | |
dc.contributor.author | Yawalkar, Nikhil | |
dc.contributor.author | Mainetti, Carlo | |
dc.contributor.author | Laffitte, Emmanuel | |
dc.contributor.author | Spehr, Christina | |
dc.contributor.author | Anliker, Mark | |
dc.contributor.author | Streit, Markus | |
dc.contributor.author | Augustin, Matthias | |
dc.contributor.author | Rustenbach, Stephan | |
dc.contributor.author | Conrad, Curdin | |
dc.contributor.author | Hafner, Jürg | |
dc.contributor.author | Boehncke, Wolf-Henning | |
dc.contributor.author | Borradori, Luca | |
dc.contributor.author | Gilliet, Michel | |
dc.contributor.author | Itin, Peter | |
dc.contributor.author | French, Lars E | |
dc.contributor.author | Häusermann, Peter | |
dc.contributor.author | Navarini, Alexander A | |
dc.date.accessioned | 2024-10-25T05:52:32Z | |
dc.date.available | 2024-10-25T05:52:32Z | |
dc.date.issued | 2016 | |
dc.description.abstract | BACKGROUND The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis. PATIENTS AND METHODS Patients with moderate to severe psoriasis are included in the SDNTT when treatment with a conventional systemic agent or biologic is initiated that was not previously used by the respective patient. Patients are followed over a 5-year period. Clinical data are obtained every 3-6 months using standardized case report forms. Here, baseline data and follow-up data for 1 year of patients included from October 2011 until December 2014 were analyzed. RESULTS Within 39 months, 323 patients from 7 tertiary dermatology centers in Switzerland were recruited in the SDNTT; 165 patients received biologics and 158 conventional systemic therapies. Patients treated with biologics had a significantly higher severity (PASI 11.3 vs. 9.2, BSA 15.6 vs.11.9, psoriatic arthritis 36.4 vs. 10.8%; p ≤ 0.005, p ≤ 0.013, p ≤ 0.001) and a longer duration of illness (19.2 vs. 14.4 years, p ≤ 0.003) compared to patients starting a conventional systemic treatment. PASI reduction was satisfying in both treatment groups, with 60.6% of patients treated with biologics achieving PASI75 after 1 year compared to 54.2% of patients receiving conventional systemic drugs (nonsignificant). On average, the drug survival in patients receiving a biologic therapy was significantly longer than those receiving conventional systemic treatments (30.5 vs. 19.2 months, p ≤ 0.001). CONCLUSIONS In the real-world setting of a prospective national therapy registry, the application of current therapeutic guidelines for patients with moderate to severe psoriasis resulted in a PASI reduction of approximately 70% within the first year of treatment, but current therapeutic targets of PASI75 and PASI90 were reached in only 58 and 36% of patients, respectively, at 1 year, highlighting a gap in efficacy between selective clinical trials and the real-world setting. | |
dc.description.numberOfPages | 8 | |
dc.description.sponsorship | Universitätsklinik für Dermatologie | |
dc.identifier.doi | 10.7892/boris.100049 | |
dc.identifier.pmid | 28076860 | |
dc.identifier.publisherDOI | 10.1159/000452740 | |
dc.identifier.uri | https://boris-portal.unibe.ch/handle/20.500.12422/152812 | |
dc.language.iso | en | |
dc.publisher | Karger | |
dc.relation.ispartof | Dermatology | |
dc.relation.issn | 1018-8665 | |
dc.relation.organization | DCD5A442BAD9E17DE0405C82790C4DE2 | |
dc.subject | Biologics Conventional systemic treatment Psoriasis Swiss psoriasis registry | |
dc.subject.ddc | 600 - Technology::610 - Medicine & health | |
dc.title | Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. | |
dc.type | article | |
dspace.entity.type | Publication | |
dspace.file.type | text | |
oaire.citation.endPage | 647 | |
oaire.citation.issue | 6 | |
oaire.citation.startPage | 640 | |
oaire.citation.volume | 232 | |
oairecerif.author.affiliation | Universitätsklinik für Dermatologie | |
oairecerif.author.affiliation | Universitätsklinik für Dermatologie | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.date.embargoChanged | 2018-01-13 01:30:12 | |
unibe.description.ispublished | pub | |
unibe.eprints.legacyId | 100049 | |
unibe.journal.abbrevTitle | DERMATOLOGY | |
unibe.refereed | true | |
unibe.subtype.article | journal |
Files
Original bundle
1 - 1 of 1
- Name:
- 452740.pdf
- Size:
- 158.27 KB
- Format:
- Adobe Portable Document Format
- File Type:
- text
- License:
- publisher
- Content:
- published